Advisor Group’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | $31K | Hold |
1,310
| – | – | ﹤0.01% | 3700 |
|
|
2019
Q3 | $25K | Hold |
1,310
| – | – | ﹤0.01% | 3802 |
|
|
2019
Q2 | $27K | Buy |
1,310
+1,000
| +323% | +$20.6K | ﹤0.01% | 3761 |
|
|
2019
Q1 | $6K | Buy |
310
+67
| +28% | +$1.3K | ﹤0.01% | 4570 |
|
|
2018
Q4 | $5K | Hold |
243
| – | – | ﹤0.01% | 4483 |
|
|
2018
Q3 | $6K | Sell |
243
-267
| -52% | -$6.59K | ﹤0.01% | 4490 |
|
|
2018
Q2 | $12K | Buy |
510
+310
| +155% | +$7.29K | ﹤0.01% | 3981 |
|
|
2018
Q1 | $6K | Hold |
200
| – | – | ﹤0.01% | 4312 |
|
|
2017
Q4 | $5K | Sell |
200
-420
| -68% | -$10.5K | ﹤0.01% | 4377 |
|
|
2017
Q3 | $17K | Hold |
620
| – | – | ﹤0.01% | 3639 |
|
|
2017
Q2 | $14K | Hold |
620
| – | – | ﹤0.01% | 3720 |
|
|
2017
Q1 | $15K | Buy |
620
+520
| +520% | +$12.6K | ﹤0.01% | 3535 |
|
|
2016
Q4 | $2K | Hold |
100
| – | – | ﹤0.01% | 4200 |
|
|
2016
Q3 | $3K | Hold |
100
| – | – | ﹤0.01% | 4049 |
|
|
2016
Q2 | $2K | Buy |
+100
| New | +$2K | ﹤0.01% | 4059 |
|